Novo Nordisk's GLP-1 Wegovy Receives EMA Approval for Heart Failure Label Update on Thursday

Sep 19, 2024, 08:00 PM

Novo Nordisk, the Danish drugmaker, announced that its drug Wegovy has received a positive opinion from the European Medicines Agency for a label update. The update will reflect reduced heart failure symptoms and improved physical function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). The recommendation, announced on Thursday, is based on results from the STEP HFpEF trials. Wegovy is the first GLP-1 medication to receive such an endorsement for obesity-related heart failure.